[News in the management of calcium and phosphorus metabolism disorders for patient treated by hemodialysis].
Bone metabolism is very frequently disturbed in end stage renal failure hemodialyzed, with secondary hyperparathyroidism development but also serious potential cardiovascular consequences. New treatments will be available very soon in Europe such as new phosphate binders, vitamin D2 analogues or calcimimetics to fight against such medical diseases, with the hope of less risk for vascular complications. The real place of such new medical opportunities needs to be determined. Moreover, studies with morbidity and mortality end-points are waited before estimating the real importance of these new therapeutic tools.
Van Overmeire
L
L
Service de néphrologie, Département de médecine, CHU Sart Tilman 4000 Liegè I, Belgique.
Delanaye
P
P
Krzesinski
J M
JM
D002118:Calcium / Q000008:administration & dosage / Q000378:metabolism*; D015913:Chelation Therapy / Q000379:methods; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000209:etiology / Q000628:therapy; D004872:Ergocalciferols / Q000627:therapeutic use; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D010758:Phosphorus / Q000378:metabolism*; D006435:Renal Dialysis / Q000009:adverse effects
D004872:Ergocalciferols; D010758:Phosphorus; D002118:Calcium